Publication | Closed Access

Linezolid reduces length of stay and duration of intravenous treatment compared with vancomycin for complicated skin and soft tissue infections due to suspected or proven methicillin-resistant Staphylococcus aureus (MRSA)

Soft Tissue InfectionsAntimicrobial SusceptibilityIntravenous TreatmentAntibioticsHealth SciencesHealthcare-associated InfectionLinezolid Reduces LengthAntimicrobial TherapyAntimicrobial ChemotherapyInfection ControlDermatologyMedicineClinical MicrobiologyAntimicrobial ResistanceDrug Resistance